



## Thrombosis and Coagulopathy

Guest Editor:

**Dr. Antonio Chistolini**

Hematology Department of  
Translational and Precision  
Medicine, Sapienza University of  
Rome, Rome, Italy

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editor

Dear Colleagues,

Cancer patients are at higher risk of developing thromboembolic events. Low-molecular-weight heparin remains the standard anticoagulant therapy in a cancer setting. However, direct oral anticoagulants have recently changed the therapeutic approach to the treatment of venous thromboembolism in cancer patients.

This Special Issue will focus on the treatment of venous thromboembolism in patients affected by solid and hematologic malignancies.

Dr. Antonio Chistolini  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Maurizio Battino**

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

*Diseases* is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

*Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023).

## Contact Us

*Diseases* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/diseases  
diseases@mdpi.com  
X@Diseases\_MDPI